Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 2,201–2,300 of 2,656
Zaihan, A. F., Hafiz, N. A. H. M., Hazamy, N. I. A. K., Termizy, A. Z., Roslan, N. I., Ganesan, P. M., Choe, S. H., & Kow, C. S. (2026) · Asian Heart Journal · doi:10.1097/ah9.0000000000000028
Wallace, H., Abdy, M. E., Anderson, K., Johns, E., Nguyen, T., Scuderi, C. E., Lee, V. W., Tunnicliffe, D. J., & Jun, M. (2026) · Internal Medicine Journal · doi:10.1111/imj.70317
Hansrivijit, P., Patorno, E., Tesfaye, H., Wexler, D. J., & Paik, J. M. (2026) · Kidney360 · doi:10.34067/kid.0000001144
Keller, S. A., Krohn, P., Chen, Z., Luciani, A., & Devuyst, O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.29.702541
“15,16 Beyond glucosuria, SGLT2i induce coordinated metabolic adaptations in PT cells that alter substrate availability and energy balance and can secondarily modulate lysosome-centered signaling pathways, including mTORC1 and autophagy–lysosome function.”
Gerdes, C., & Wolf, G. (2026) · Diabetes aktuell · doi:10.1055/a-2759-5230
Georgianos, P. I., Vaios, V., Roumeliotis, A. K., & Liakopoulos, V. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106361
PET-Derived Renal Perfusion Provides a Window Into Cardiorenal Risk Beyond Filtration
Patel, K. K., & Dilsizian (2026) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.126.019570
Huang, C., Lai, E. C., Wu, V., Hsieh, M. H., Li, C.-J., Chang, R., Chen, J.-S., Tsai, Y.-S., & Sung, J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag028
Matsui, M., Kosugi, T., Kitamura, S., Nishimoto, M., Itano, A., Yamamoto, M., Yabuta, H., Oda, A., Kawakami, M., Tsushima, H., et al. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2624169
“…well as lifestyle modifications with respect to nutrition and physical activity [3,4]. the emergence of SGlt2 inhibitors (SGlt2is) has markedly transformed the management of CKd, particularly because of their ability to delay disease progression and reduce the risk of incident heart failure [5,6].”
Cardiovascular-kidney-metabolic syndrome (literature review)
Ashcheulova, T. V., Herasymchuk, N. M., Амбросова, Т. М., Kochubiei, O., & Herasymchuk, U. S. (2025) · Inter Collegas · doi:10.35339/ic.2025.12.3.aha · Cited by 1
Zhang, Y. R., Wang, L., Wu, J., Wan, N., Liu, X., Lin, M., Li, J., Wang, J., Wu, J., Peng, J., et al. (2026) · hLife · doi:10.1016/j.hlife.2025.12.010
Besteiro, B., Ribeirinho-Soares, P., Elias, C., Vale, C., PINTO, C., Vieira, J. T., Matos, M. M., Brito, M. T., Matias, P., Gomes, F., et al. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.10.007
Joy, M. S., Gbadegesin, R., Conway, P. T., Chertow, G. M., Liu, K. D., Lim, M. D., Kretzler, M., Bonventre, J. V., & Moderators, O. B. O. T. P. M. W. S. A. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001031
Hara, R., Yamahara, H., Hirakawa, Y., Hashiba, T., Keying, H., Tabata, H., & Nangaku, M. (2026) · Nephrology · doi:10.1111/nep.70176 · Cited by 1
Kyriakidou, A., Shekhda, K. M., Waung, J. A., & Tzoulis, P. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf336 · Cited by 1
“Empagliflozin is approved for type 2 diabetes mellitus, heart failure, and chronic kidney disease [25, 26].”
Speer, T. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag039
Lv, X., Lu, C., Liu, H., Wei, H., Xu, J., He, D., Yan, C., & Shao, W. (2026) · American Journal of Nephrology · doi:10.1159/000550928 · Cited by 3
Documento de posicionamiento de SEMERGEN sobre la enfermedad renal crónica
Pérez-León, N., García, J. P., Alonso-Álvarez, M. P., & Martínez-Berganza-Asensio, L. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102690 · Cited by 1
Mineralocorticoid Receptor Antagonist and Its Combinations in Heart Failure
Varghese, K., George, J., Khanna, R., Rath, J. K., Sinha, K. K., Dargad, R. R., Gutghe, S., Shah, T., Ganatra, L., Bhatt, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1301
Wang, M., & Gao, F. (2026) · Human Genomics · doi:10.1186/s40246-026-00930-1 · Cited by 1
Azak, A., Avşar, M., Koçak, G., et al. (2026) · medRxiv · doi:10.64898/2026.02.20.26346726
Kahlon, B., Gohel, B., Jassemi, S., & Donald, M. (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251391264
Wang, T., & Du, Y. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00938-8
“However, this assumption may not hold in certain clinical contexts, such as with drugs in the class of SGLT2 inhibitor, which have been shown to produce an acute, early decline in eGFR followed by a more gradual chronic decline (Heerspink et al., 2020; Group, 2023; Perkovic et al., 2019).”
Im, S. (2026) · Endocrinology and Metabolism · doi:10.3803/enm.2026.2948
Iwamoto, T., Hidaka, S., Iwamoto, M., & Shibata, H. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109308
Sosa, A., & Sosa, M. C. (2026) · Cureus · doi:10.7759/cureus.104564
“…canagliflozin benefit in diabetic kidney disease with albuminuria, while DAPA-CKD and EMPA-KIDNEY broadened evidence to include patients with and without diabetes, showing reductions in sustained eGFR decline, end-stage kidney disease (ESKD), and renal or cardiovascular death endpoints [5-7].”
Doku, A., EL‐HARARI, M. B., Badr, A., Bennis, A., Ogola, E. N., AlHabeeb, W., Abdelhamid, M., & Mbakwem, A. C. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043650 · Cited by 1
Sodium-Glucose Cotransporter-2–inhibitors in Adult Patients With Alport Syndrome
Toso, D., Cinquina, V., Econimo, L., Cortinovis, R., Zeni, L., Tornambè, V., Dordoni, C., Ritelli, M., Savoldi, G., Mazza, C., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106417 · Cited by 1
Omrani, M. A., Baskaran, B. S., Sadeghi, H., Ahmadi, F., Eddin, L. E., Jafari, A., & Muanda, F. T. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2641874 · Cited by 2
Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial
Eadon, M. T., Cavanaugh, K. L., She, L., Steen-Burrell, K.-A., Mohottige, D., Nadkarni, G. N., Kitzman, H. E., Chakraborty, H., Empey, P. E., Limdi, N. A., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0528 · Cited by 1
Chang, C.-H., Kuo, Y.-C., Kuan, Y., Lim, P.-S., Chung, M., Pan, Y.-R., Luo, C.-W., & Wu, T.-K. (2026) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2026.100709 · Cited by 3
Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors
Inzucchi, S. E., & Kosiborod, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00012-4
Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future
Everett, B. M., Pagidipati, N. J., & Wang, C. C. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00011-2
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Kuwagata, S., Chin‒Kanasaki, M., Yamada, A., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70277
“…blood pressure management with renin – angiotensin – aldosterone system (RAAS) inhibitors 5,6 , and additional use of sodium-glucose co-transporter 2 (SGLT2) inhibitors 7 – 9 and/or glucagon-like peptide 1 receptor agonists (GLP-1RA) 10 – 12 , can reduce proteinuria and improve renal prognosis.”
Nobayashi, H., Satoh, M., Hirose, T., Nakayama, S., Iwabe, Y., Hashimoto, H., Murakami, T., Okada, K., Mori, T., & Metoki, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70625 · Cited by 1
Inhibidores de la SLGT-2 en el manejo de enfermedad renal crónica en pacientes no diabéticos
Cadena, A. E., Pastrana, J. C. G., & Oltra, G. (2026) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v46i1.1279
Coleman, P., Keenan, B., Monaghan, M., Glass, R., Gardner, S., Fleming, G. F., & Scott, M. G. (2026) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2025-004897
Huang, L., & Yi, M. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04842-z
“…study, while somewhat smaller than the landmark DAPA-CKD and EMPA-KIDNEY trials which reported 39% and 28% relative risk reductions respectively, nonetheless demonstrates meaningful clinical impact in a real-world setting with broader patient eligibility and usual-care background therapy [5, 20].”
Cardio-renal-metabolic syndrome and its management in clinical practice
Šatný, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.091
Kim, B.-J., & Song, K.-H. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1791139
“In human medicine, these combined hemodynamic and renal mechanisms have supported the expansion of SGLT2i use in heart failure and CKD populations, including patients without diabetes (8–12).”
Hung, C.-M., Hsu, C., Zeng, B.-S., Suen, M., Chen, J.-J., Zeng, B., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T.-Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062619
Microbial metabolites as promising alternatives to empagliflozin for type 2 diabetes management
Rakib, A. R., Bristy, T. A., Shifa, J., Surovi, S., Banik, M., Bushra, A., Sultana, T., Joyoti, S. A., Mahmud, M. T., Ahmed, F., et al. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00779-3
Renal failure isn't just a nephrologist problem
Cice, G. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag038
Was ist neu in der Therapie des Typ-2-Diabetes?
Gallwitz, B. (2026) · CME · doi:10.1007/s11298-025-4487-x
Prävention und Progressionshemmung der chronischen Nierenerkrankung
Schmit, D., Lämmerzahl, J. R., Neuhaus, S., & Sellier, A. B. (2026) · Die Nephrologie · doi:10.1007/s11560-026-00911-4
Miyazawa, I., Araki, S.-I., Yokoyama, H., Kume, S., & Maegawa, H. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109309
Yeh, H., Lu, H., Lin, L.-Y., & Chien, L. (2026) · Sage Open Chronic Disease · doi:10.1177/27558428261421697
Cardio‑Reno‑Metabolic Syndrome: A Decade of Evidence (2014–2024)
Duranti, E. (2026) · Journal of Cardiology and Cardiovascular Medicine · doi:10.29328/journal.jccm.1001223
Endothelial triple-pathway vasorelaxation as an adjunctive strategy in resistant hypertension
Madeddu, P., Cattaneo, M., Giuffre, M., & Laffin, L. J. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004286
Phan, H. H., Le, A., & Do, M. D. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00578-2
Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection
Lee, H.-J., Chiang, C.-H., Kuo, S.-C., Chu, C., Lin, S. J., & Chang, T. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117923
Darbà, J., Ascanio, M., & Rodríguez, A. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01611-6
Guo, J., Ma, H., Xu, Y., Chen, Z., Tang, Y., & Li, J. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04859-4
“Despite active treatment, many patients continue to experience a progressive decline in estimated glomerular filtration rate (eGFR) along with persistent proteinuria [3, 4].”
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01461-y
Umfassende kardiorenale Protektion durch SGLT2-Hemmer
Rawish, E., & Eitel, I. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02098-1
Jaiswal, V., Mashkoor, Y., Waqas, M., Khan, M. S., Ahmed, A. B., Deb, N., Banach, M., Dani, S. S., Zelniker, T. A., Alexander, K. M., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.024
Halimi, S. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.03.003
Management of Diabetic Kidney Disease
Ayyagari, U. (2025) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071261427510
Movila, D. E., Motofelea, A. C., Dragan, S. R., Schiller, A., Ionac, A., Motofelea, N., & Căruntu, F. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073168
Adıyaman, M., Bora, R., Toprak, B., et al. (2026) · The Heart Surgery Forum · doi:10.31083/hsf47635
Bianchi, L., Afonso, L. M., Chendey, T., Modumudi, S., Minghini, A., Verdonschot, J. A. J., & Heymans, S. R. B. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101906 · Cited by 1
Finerenone in heart failure with ejection fraction ≥40%: state of the art and future perspectives
Llàcer, P., Marcos, M. C., Núñez, J. E., Perez-Belmonte, L. M., Pérez-Silvestre, J., Martéles, M. S., & Colet, J. C. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502520
Paes, B. D. N. P., Reis, D. M., Villela, M. C. S., & Silva, B. D. A. M. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i1.478
Chen, Y., Zheng, S.-C., Bai, Y., Deng, W.-Z., Gong, N., Fu, Y., Zhang, Z.-Y., Chen, X.-M., Hong, Q., & Sun, X. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117942 · Cited by 1
Sasaki, T., Micallef, S., Wang, A. Y., Butt, F., Hammond, N. E., Hardie, M., Knowles, S., Yokoo, T., & Gallagher, M. (2026) · Critical Care and Resuscitation · doi:10.1016/j.ccrj.2026.100175 · Cited by 2
Imaizumi, T., Asada, S., Ono, H., Kanai, S., & Araki, S.-I. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02851-8
Kasahara, K., Okada, H., Ide, H., Nakajima, H., Ushigome, E., Nakanishi, N., Hamaguchi, M., Kurogi, K., Murata, H., Tsuda, E., et al. (2026) · Obesity · doi:10.1002/oby.70186
“Therefore, when evaluating the onset of such diseases, factors other than the achievement of 2cm2kg may also be involved, and caution is warranted in interpreting the results [33, 34].”
Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review
Soto-Santillán, P., Jacobo-Ruvalcaba, A., de Lay, M. W., & Orihuela-Rodríguez, Ó. (2026) · Biomedicines · doi:10.3390/biomedicines14040841
Étude du rôle des calpaïnes dans les complications microvasculaires du diabète
Salemkour, Y. (2023) · theses.fr (ABES) · doi:10.70675/36e8b2eezb42ez4ac4zac09z6f519c78839a
Trenas, A., Prieto-Laín, N., Gómez-Hernández, A. I., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19040583 · Cited by 1
Barreto, E. F., Nieves, Y. A. G., Johnson, E. C., Eder, T. H., Gerberi, D., KASHANI, K. B., Kattah, A. G., Liu, K. D., May, H. P., McCoy, R. G., et al. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70137 · Cited by 1
“There is growing evidence that SGLT2i and GLP-1 RA decrease CKD progression in patients with and without diabetes [9–11].”
Kushner, P. R., & Mende, C. W. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0017 · Cited by 1
Cutrell, S., Patino, K., Babalola, R. O., Murchie, M., & Bucheit, J. D. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261431283
Tsai, S.-F., Liu, W.-J., Lin, Y.-J., & Lee, C.-L. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01118-z
“…[3], in addition to pharmacologic therapies such as renin–angiotensin system inhibitors [4–6], sodium–glucose co-transporter 2 inhibitors [7, 8], and finerenone [9, 10] and GLP-1 receptor agonists [11], life-style modification (including dietary approaches) (from 2020 KDOQI guideline) [12]…”
VII. Therapeutic Strategies for Diabetic Kidney Disease
Kawanami, D. (2025) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.114.656
Effectiveness of check-up 35 for detecting targeted diseases in Germany
Kommer, A., Weinmann-Menke, J., Kostev, K., & Labenz, C. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03307-4
“Therefore, measures should be intensified in sharing the recently published evidence on the positive studies investigating SGLT2-inhibotors on the progression of CKD [22, 23].”
Nobayashi, H., Satoh, M., Hirose, T., Nakayama, S., Iwabe, Y., Yagihashi, T., Hashimoto, H., Murakami, T., Okada, K., Mori, T., et al. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02865-2
Sarwal, A., Throolin, M. J., Wei, G., Nevers, M. R., Hartsell, S. E., Shen, J., Boucher, R. E., & Beddhu, S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.04.004
Huang, H.-E., Jan, J., Lin, Y.-S., Lin, C.-L., Lin, M.-H., Kuo, T.-Y., Yen, P.-C., Li, C.-Y., & Chang, S. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07446-2
“SGLT2i are well-documented for their renoprotective effects in T2DM patients, with evidence showing reduced progression of renal impairment across different age groups [9, 10, 25–27].”
Yang, Y., Zhou, W., Yang, M., Tang, S. C. W., & Liu, B.-C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1800868 · Cited by 1
Llàcer, P., Marcos, M. C., Nuñez, J., Perez-Belmonte, L. M., Pérez-Silvestre, J., Marteles, M. S., & Colet, J. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502520
Siriyotha, S., Tansawet, A., Pattanaprateep, O., Kongmalai, T., Looareesuwan, P., Yang, J., Boonmanunt, S. W., McKay, G. J., Attia, J., & Thakkinstian, A. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04980-4
“Even though SGLT2is were comparable to each other in terms of their efficacy (i.e., hazard ratios between 0.61 and 0.72 compared to placebo for composite renal endpoints) [6–8], the cost of individual medications can vary significantly [26].”
InfluentialZaihan, A. F., Hisham, S. A., Hafiz, N. A. H. M., Hazamy, N. I. A. K., Termizy, A. Z., Roslan, N. I., Ganesan, P. M., Yahaya, N. A., Wong, Z. Y., Arqam, M. I. M., et al. (2026) · Frontiers in Health Services · doi:10.3389/frhs.2026.1784432
Kuwagata, S., Chin‒Kanasaki, M., Yamada, A., Sakae, T., Ishimoto, N., Imamura-Uehara, Y., Sugahara, S., Yamahara, K., Yasuda‒Yamahara, M., Tanaka‒Sasaki, Y., et al. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02860-7
Chen, J., Ho, W., Chen, M. Y., Fang, Y.-W., Tsai, M., & Hsiao, C.-C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70764
“297, with robust cardiorenal benefits demonstrated in major RCTs, including CREDENCE, DAPA-CKD and EMPA-KIDNEY [4–8].”
Gembillo, G., Visconti, L., Tranchida, V., Nardi, C., Calimeri, S., Gambuzza, M. E., Princiotto, M., Chinigò, C., Soraci, L., & Santoro, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115058 · Cited by 2
Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors
Elezaby, A., Nayor, M. G., & Alexander, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00096-0
Cintrón-García, J. J., Patel, M., Andersen, C. R., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106538
Lejsková M.: Selected cardiovascular, renal and metabolic study results published in 2024
Lejsková, M. (2026) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2026.007
Rajput, J., Rajput, P. V., Jena, N., Kumar, A. K. M. A., Mohanty, E., & Parsi, S. (2026) · Cureus · doi:10.7759/cureus.107083
Olesen, R. H., Carlson, N., Søndergaard, J., Ballegaard, E. L. F., Borg, R., & Ehlers, L. H. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101363
Brandenburg, V. (2026) · Nephrologie aktuell · doi:10.1055/a-2748-5190
Brademeyer, A., Jenkins, C. A., Kampe, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.028
RAAS blockade in the kidney life-cycle–treatment standard
Moriconi, D., García-Carro, C., Núñez, J. E., Correa‐Rotter, R., Tuttle, K., & Soler, M. J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag090 · Cited by 1
Roy, S., Basu, M., Mukhopadhyay, P., & Ghosh, S. K. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1337
Anticholinergic Burden and Progression to Kidney Replacement Therapy
Mouheb, A., Massy, Z. A., Metzger, M., Levassort, H., Pépin, M., Laville, M., de Pinho, N. A., Laville, S. M., Liabeuf, S., de Pinho, N. A., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106552
Ruste, M., Vieira, A., Guennec-Lux, Y. L., Berthod, C., Pozzi, M., Mewton, N., Fellahi, J.-L., & Jacquet‐Lagrèze, M. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.01.004
Suh, S.-H.-O., Lee, D., Ma, S., Yoo, S., & Kim, S. (2026) · JMIR Public Health and Surveillance · doi:10.2196/88408
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.